GLI1 and ovarian carcinoma: Indeed, GANT61 has become the reference compound for CSC-targeted therapies as it proved to inhibit the Hh pathway at Gli level in several cancer cells, CSCs and tumor animal models, such as pancreatic [17], prostate [14], lung [12], colon and hepatocellular cancer [50,51], as well as in tumors for which the role of Gli was not elucidated before, including ovarian cancer [52], esophageal adenocarcinoma and melanoma [8,53].